We are excited to congratulate the Hong Kong Med-Tech Association (HKMTA) on their new name, reflecting a stronger focus on technology. Our President and Managing Director, Jennifer Che, along with Principal Pauli Wong, were thrilled to celebrate this significant milestone with the organization at the recent HKMHDIA Medical Fair Forum.

Pauli, the official IP Advisor to HKMTA, joined Jennifer, one of the keynote speakers at the event, who shared about the importance of a well-thought-out intellectual property strategy for healthcare inventions. Jennifer emphasized the challenges of protecting biomedical products that operate at the intersection of regulatory affairs, IP, trade secret, and data privacy, particularly in the complex, multijurisdictional landscape of the Greater Bay Area (GBA). The event fostered valuable discussions on navigating these complexities, reinforcing our commitment to helping innovators safeguard their groundbreaking ideas.

我們過去活動

Recommended Insights

China Forges Ahead with Draft Measures for New Patent Linkage System

2020年10月19日
Update! The finalized Implementation Measures are now out. You can read the details here: Breaking: China Released New Implementation Measures for the New Patent Linkage System Last month September 11, 2020, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) jointly issued a draft set of measures for public opinion […]

CHINA: New Patent Examination Guidelines Now Available for Public Comment

2021年8月4日
Two months after the new Chinese Patent law came into effect, the CNIPA has released a new set of Patent Examination Guidelines (proposed version) for public comments on Aug 3, 2021. Here are the explanation of the amendments (Chinese only). Here is the full set of proposed amendments (Chinese only). Briefly, the new amendment focuses […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]

AI, Big Data, and Blockchain - CNIPA seeks public comment on draft patent examination guidelines

2019年11月21日
Exciting new changes continue to happen with the Chinese Patent Office (CNIPA). On November 12, 2019, the CNIPA published a new set of amendments to Part II Chapter 9 of the Patent Examination Guidelines (“Draft”) and requested public comment by December 11, 2019. In summary, the new guidelines clarify how emerging technologies involving artificial intelligence, […]
Top crossarrow-right